Hematology Oncology Toxicology, Office of Oncologic Diseases, Ctr for Drug Evaluation & Research
US Food & Drug Administration
Dr. Saber is the Deputy Director in the Division of Hematology Oncology Toxicology (DHOT), in the Office of Oncologic Diseases, in CDER. In this role she provides leadership for day-to-day activities, leads and coordinates scientific research, and participates in guidance development. Dr. Saber has extensive industry and regulatory experience. She served as a Subject Matter Expert assisting pharmaceutical companies worldwide in nonclinical drug development and served many roles at the FDA over 18 years. Dr. Saber is recognized for her efforts in establishing acceptable approaches in first-in-human dose selection for new classes of products. She was the lead author of several manuscripts describing approaches and models used for dose selection. Dr. Saber received her PhD in Biochemistry from Lehigh University and conducted her post-doctoral studies at Fox Chase Cancer Center, PA.
Monday, September 11, 2023
1:30 PM - 5:00 PM PT
Disclosure(s): No financial relationships to disclose
2 - First-in-Human Dose Selection of Immune-activating Biotherapeutics in Oncology
Monday, September 11, 2023
1:30 PM - 5:00 PM PT
Disclosure(s): No financial relationships to disclose